Moderna (MRNA) Return on Capital Employed (2019 - 2026)

Moderna (MRNA) has 8 years of Return on Capital Employed data on file, last reported at 35.85% in Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 35.85%, down 430.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 35.85% (down 430.0% YoY), and the FY2025 annual result was 27.32%, up 71.0% from the prior year.
• Return on Capital Employed declined to 35.85% in Q1 2026 per MRNA's latest filing, from 29.99% in the prior quarter.
• Over five years, Return on Capital Employed peaked at 96.19% in Q1 2022 and troughed at 35.85% in Q1 2026.
• A 5-year average of 0.54% and a median of 26.62% in 2023 frame the typical range for Return on Capital Employed.
• The sharpest annual moves came in 2022 and 2023: Return on Capital Employed surged 5592 bps in 2022, then tumbled 8523 bps in 2023.
• A 5-year view of Return on Capital Employed shows it stood at 44.78% in 2022, then sank by 159 bps to 26.62% in 2023, then declined by 16 bps to 30.9% in 2024, then rose by 3 bps to 29.99% in 2025, then retreated by 20 bps to 35.85% in 2026.
• Business Quant data shows MRNA's Return on Capital Employed at 35.85% in Q1 2026, 29.99% in Q4 2025, and 33.33% in Q3 2025.